Paper Details

  1. Home
  2. Paper Details

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Author: FeaganB G, InnesA, LichtensteinG, PatelJ, Radford-SmithG, SandbornW J

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

CDP571 was ineffective for sparing steroids in patients with steroid-dependent Crohn's disease.
Paper Details　
Original Abstract of the Article :
BACKGROUND: More than 50% of patients with Crohn's disease become either steroid resistant or dependent. Accordingly, development of new treatments for steroid-dependent Crohn's disease is a research priority. AIM: To evaluate CDP571, a humanized antibody to tumour necrosis factor-alpha, for the tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.2006.02791.x

データ提供：米国国立医学図書館（NLM）

Evaluating a New Treatment for Crohn's Disease: CDP571

The world of medicine is a vast desert, constantly searching for oases of solutions for debilitating diseases. Crohn's disease, a chronic inflammatory bowel condition, presents a particularly challenging landscape. This research delves into the effectiveness of CDP571, a humanized antibody targeting tumor necrosis factor-alpha, as a potential treatment for patients with steroid-dependent Crohn's disease.

The study, conducted as a randomized, double-blind, placebo-controlled trial, aimed to assess the ability of CDP571 to help patients reduce or eliminate their dependence on steroids. The researchers meticulously evaluated the effectiveness of CDP571 by comparing it to a placebo group, ensuring a fair and unbiased comparison. The results revealed that CDP571 was not successful in reducing steroid dependence in patients with Crohn's disease. This finding, while not the desired outcome, is valuable knowledge in our journey to find effective treatments for this complex condition.

CDP571: A Missed Oasis in the Crohn's Desert

This research, although it didn't find CDP571 to be a successful oasis in the Crohn's desert, is an important step in our ongoing quest for solutions. The study highlights the importance of rigorous testing and the need to continue exploring new treatment options for this challenging disease.

Navigating the Crohn's Landscape: What Does This Mean for Patients?

While CDP571 didn't prove to be the answer, the study underlines the importance of working closely with healthcare professionals to find the most effective treatment for individual needs. It's important to remember that research is an iterative process, and new discoveries are constantly being made. The desert of Crohn's disease may seem vast, but with persistent exploration, we can find new ways to improve the lives of those affected.

Dr. Camel's Conclusion

The search for a solution to Crohn's disease is a long and winding trek across the desert. We can't give up! This study reminds us that even when a promising trail leads to a dead end, every step in the journey brings us closer to finding an oasis of relief.

Date :
  1. Date Completed 2006-06-29
  2. Date Revised 2018-12-24
Further Info :

Pubmed ID

16480401

DOI: Digital Object Identifier

10.1111/j.1365-2036.2006.02791.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.